AXXDH
AXXDH, also known as AXXDH-1, is a synthetic cannabinoid receptor agonist that has gained attention for its potential therapeutic uses and its role in the synthetic cannabinoid market. It was first synthesized in 2013 by a research group led by Dr. John W. Huffman at the University of Pennsylvania. AXXDH is a derivative of the synthetic cannabinoid JWH-018, with a modified structure that enhances its affinity for the CB1 receptor, the primary target of many cannabinoids in the body.
AXXDH has been studied for its potential therapeutic applications, including the treatment of pain, inflammation, and
AXXDH has also been detected in the synthetic cannabinoid market, where it is often sold under various
In summary, AXXDH is a synthetic cannabinoid receptor agonist with potential therapeutic applications and a presence